Clinical trials for Idiopathic multidrug-resistant nephrotic syndrome
9 recruiting or active trials synced from ClinicalTrials.gov.
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data- RECRUITINGPhase 2NCT06664814An Open-Label Phase 2 Study of N-Acetyl-D-Mannosamine (ManNAc) in Subjects With Primary Focal Segmental GlomerulosclerosisNational Human Genome Research Institute (NHGRI) · PI: William A Gahl, M.D.
- RECRUITINGPhase 3NCT07220083A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS)Boehringer Ingelheim
- RECRUITINGPhase 2NCT07268638A Study of Praliciguat in Participants With Focal Segmental Glomerulosclerosis (FSGS)Akebia Therapeutics
- RECRUITINGPhase 2NCT06500702A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change DiseaseSanofi
- RECRUITINGPHASE1, PHASE2NCT06090227AMPK-activation by Metformin in FSGS: AMP-FSGSYale University · PI: Madhav Menon, MD
- RECRUITINGNCT05650619Recurrence Post-transplant Observational Study in Focal Segmental Glomerulosclerosis and Minimal Change DiseaseUniversity of Michigan · PI: Eloise Salmon, MD
- RECRUITINGN/ANCT04065438Post Approval Study for Treatment of Drug-resistant Adult and Pediatric Primary FSGS Using the LIPOSORBER® LA-15 SystemKaneka Medical America LLC
- ACTIVE NOT RECRUITINGPhase 3NCT03493685Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS)Travere Therapeutics, Inc. · PI: Radko Komers, MD, PhD
- RECRUITINGN/ANCT02235857Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in ChildrenKaneka Medical America LLC · PI: Jeffrey I Silberzweig, MD